Wie hoch ist der Preis für AP Biosciences Inc (6945)

Preis für AP Biosciences Inc (6945) ist $3.06

Wie hoch ist die Marktkapitalisierung für AP Biosciences Inc (6945)

Marktkapitalisierung für AP Biosciences Inc (6945) ist $296.40M

AP Biosciences Inc (6945) KUV

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.

Jahr	P/S-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/S-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/S-Verhältnis	P/S-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	10.95	-	US
Argenx SE ARGX.US	12.19	-	NL
Moderna, Inc. MRNA.US	24.99	-	US
CSL Limited CSL.AX	3.75	-	AU
Lonza Group AG LONN.SW	-	-	CH

Unternehmen

P/S-Verhältnis

P/S-Verhältnis-Differenz

Land